The Problem: $10 Billion in Medical Device Imports
India imports 80% of its medical devices—CT scanners, MRI machines, pacemakers, stents, ventilators. Pre-COVID, this was just expensive. Post-COVID, it became a national security issue.
Remember April 2020? India couldn't get ventilators because global supply chains were broken. Hospitals were paying ₹15-20 lakh for ventilators that cost ₹5-8 lakh pre-pandemic. Result: PLI for Medical Devices (₹3,420 Cr), National Medical Devices Policy 2023 targeting $50B industry by 2030, and import substitution mandates for government hospitals.
Where Indian Companies Can Win: Not MRIs, But Everything Else
Point-of-Care Diagnostics (₹15,000 Cr Market): Testing at the patient's bedside—blood glucose meters, rapid antigen tests, portable ECG devices, handheld ultrasound. 65% of Indians live in rural areas with poor lab access. Indian advantage: cost-sensitive design (₹5,000 handheld ultrasound vs. ₹20 lakh full machine), ruggedized for Indian conditions, smartphone integration. Success stories: Niramai (breast cancer screening, ₹2,000 vs. ₹5,000 mammogram), Mylab (COVID tests exported to 40+ countries).
Medical Consumables (₹25,000 Cr Market): Syringes, catheters, IV sets, surgical gloves—60% imported despite being low-tech. Build to international quality (ISO 13485, CE Mark, FDA) and undercut imports by 30-40%. PLI: ₹1,500 Cr for consumables.
Implants & Prosthetics (₹8,000 Cr Market): Orthopedic implants, dental implants, cardiac stents, prosthetic limbs. Meril Life: cardiac stents, ₹1,200 Cr revenue, exports to 100+ countries. High-margin, government hospitals mandated to prefer domestic.
Biotech Hardware (₹5,000 Cr Market): PCR machines, cell counters, incubators, bio-reactors, microscopes—90%+ imported. Opportunity to build at 50-60% of import price with local service.
The Regulatory Reality: It's Harder Than You Think
Medical devices aren't like software—if your device breaks, people die. India requires CDSCO approval, ISO 13485 certification, BIS standards, and clinical trials for Class C/D devices. Timeline: 18-36 months.
Export markets: FDA 510(k) costs $500K-2M, CE Mark $200K-500K. You need ₹3-5 Cr just for regulatory approvals and 2-3 years before you can sell. Most startups die here—not because the technology doesn't work, but because they run out of money.
Our Founder LPs include people who've navigated CDSCO, FDA, and CE Mark processes. They know what 'good regulatory documentation' looks like.
The Funding Gap: Between Prototype and Clinical Trials
Biotech/health tech has the longest, most expensive valley of death. TRL 1-4 (lab prototype): covered by BIRAC grants (₹50L-2 Cr). TRL 8+ (commercial sales): covered by Series A VCs (₹20-50 Cr). But TRL 5-7 (clinical trials, regulatory): needs ₹5-15 Cr and is NOT covered.
₹5-15 Cr buys clinical trials (₹2-5 Cr for multi-site), regulatory approvals (₹1-3 Cr for CDSCO/FDA/CE), manufacturing setup (₹2-5 Cr for ISO 13485 facility), and quality systems. VCs don't fund this because they can't evaluate clinical performance, don't understand 18-36 month regulatory timelines, and want SaaS-like margins.
The Distribution Challenge: Getting into Hospitals
Building the device is hard. Selling it is harder. Government hospitals: tender-based. Private hospitals: relationship-driven. Diagnostics labs: volume deals with 60-90 day payment cycles.
How Indian companies win: Government mandate for domestic preference (Meril, IKS, Poly Medicure getting large orders). Cost advantage (cardiac stent: ₹30,000 domestic vs. ₹80,000 imported). Service and support (same-day repairs vs. GE/Siemens 2-4 weeks). Customization (Indian body types, Indian diseases, local language interfaces).
The Export Opportunity: Africa, Middle East, Southeast Asia
India is the 'pharmacy of the world' (60% of global vaccine supply, 40% of generic drugs). Can we do the same for medical devices? Early signs say yes: Meril exports to 100+ countries ($150M+), Mylab exports COVID tests to 40+ countries, IKS Health exports orthopedic implants to Middle East.
Indian-made devices cost 50-70% less than US/European equivalents. African and Southeast Asian countries can't afford $50,000 ventilators but can afford $15,000 Indian ventilators. ISO 13485 + CE Mark ensures international quality. Post-COVID, countries want supply chain diversification—India is a 'trusted alternative' to China.
What Success Looks Like by 2030
Domestic medical device market: $50B (10-12% CAGR). Import dependency: 80% → 50% (₹1 lakh Cr saved). Exports: ₹50,000+ Cr. 300,000+ jobs in medical device manufacturing. 20+ medtech companies with ₹500+ Cr revenue.
China went from 80% imports and copycat products in 2010 to 60% domestic and innovation leaders (Mindray, United Imaging) in 2023—13 years. India has government support, 1.4 billion people of domestic demand, pharma manufacturing base, and biomedical engineering talent from IITs and IISc. The missing piece: ₹5-15 Cr capital to bridge clinical trials and regulatory approvals. That's what we fund.